Literature DB >> 7975827

Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs.

B E Ivins1, P F Fellows, G O Nelson.   

Abstract

The efficacy of an anthrax vaccine licensed for human use, MDPH-PA, was tested in guinea-pigs intramuscularly challenged with 10, 100 or 1000 LD50 of spores from two virulent strains of Bacillus anthracis, Vollum 1B and Ames. As demonstrated in other investigations, immunization with MDPH-PA provided better protection against challenge with the Vollum 1B strain than with the Ames strain, although vaccine efficacy against the Ames strain was better than previously reported. Enzyme-linked immunosorbent assay of serum antibody titres to B. anthracis protective antigen showed that there was no significant correlation between survival and antibody titres.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975827     DOI: 10.1016/0264-410x(94)90027-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Morphogenesis of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Joel Bozue; Christopher Cote; Theresa Wenzel; Krishna-Sulayman Moody; Michael Mallozzi; Matthew Ryan; Rong Wang; Ryszard Zielke; Janine R Maddock; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.

Authors:  J Bozue; C K Cote; K L Moody; S L Welkos
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

4.  Localization and assembly of proteins comprising the outer structures of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Michael Mallozzi; Joel Bozue; Krishna-Sulayman Moody; Alex Slack; Dengli Qiu; Rong Wang; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  Microbiology (Reading)       Date:  2009-04       Impact factor: 2.777

5.  Role of purine biosynthesis in Bacillus anthracis pathogenesis and virulence.

Authors:  Amy Jenkins; Christopher Cote; Nancy Twenhafel; Tod Merkel; Joel Bozue; Susan Welkos
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 6.  Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.

Authors:  Andrew J Phipps; Christopher Premanandan; Roy E Barnewall; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

7.  Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence.

Authors:  Joanne E Thwaite; Stephen Hibbs; Richard W Titball; Timothy P Atkins
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

9.  Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax.

Authors:  Cynthia A Rossi; Melanie Ulrich; Sarah Norris; Douglas S Reed; Louise M Pitt; Elizabeth K Leffel
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 10.  Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Authors:  Charles E Binkley; Sandro Cinti; Diane M Simeone; Lisa M Colletti
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.